Akebia Therapeutics, Inc. affirmed revenue guidance for the year 2022. For the year, the company affirm 2022 net product revenue guidance for Auryxia of $170 million - $175 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.91 USD | -3.19% |
|
-14.95% | -26.61% |
May. 09 | Transcript : Akebia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q1 Revenue $32.6M | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.61% | 191M | |
+15.19% | 121B | |
+19.91% | 114B | |
+8.24% | 23.61B | |
-19.80% | 20.43B | |
-16.19% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+2.13% | 13.54B |
- Stock Market
- Equities
- AKBA Stock
- News Akebia Therapeutics, Inc.
- Akebia Therapeutics, Inc. Affirms Revenue Guidance for the Year 2022